Global Regulatory Affairs Outsourcing Market

Medical device outsourcing is a process in which a company outsources the manufacturing process of a medical device to another company. The main types of products in medical device outsourcing are finished goods, electronics, and raw materials. Products that have passed or completed the production process but have not yet been sold or dispersed to the ultimate consumer are referred to as finished goods. The various device types are class I devices, Class II devices, and class III devices that provide services such as quality assurance, regulatory affair services, product design development, product testing, and sterilization, product implementation, product upgrade, product maintenance, and contract manufacturing. It has various applications including drug delivery, dental, diabetes care, cardiology, endoscopy, IVD, ophthalmic, diagnostic imaging, orthopedics, and general and plastic surgery. The medical device outsourcing market research report is one of a series of new reports from The Business Research Company that provides medical device outsourcing market statistics, including medical device outsourcing industry global market size, regional shares, competitors with a medical device outsourcing market share, detailed medical device outsourcing market segments, market trends and opportunities, and any further data you may need to thrive in the medical device outsourcing industry. This medical device outsourcing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global medical device outsourcing market size grew from $114.95 billion in 2022 to $129.4 billion in 2023 at a compound annual growth rate (CAGR) of 12.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The medical device outsourcing market size is expected to grow to $204.25 billion in 2027 at a CAGR of 12.1%. The prevalence of chronic diseases is expected to propel the growth of the medical device outsourcing market going forward. Chronic diseases are the conditions that last 1 year or more and require ongoing medical attention or limit activities of daily living or both. The rising chronic diseases increase the demand for new quality medical products in less launch time thereby driving the growth of the medical devices outsourcing market. For instance, according to the UN Chronicle, a digital magazine of the United Nations, the global burden of chronic diseases is expected to reach about 56% by 2030. Therefore, the prevalence of chronic diseases will drive the growth of the medical device outsourcing market. Strategic partnerships and collaborations have emerged as a key trend gaining popularity in the medical device outsourcing market. Major companies operating in the market are focusing on partnerships and collaborations to lead the market. For instance, in December 2021, Labcorp, a US-based laboratory testing company acquired Toxikon Corporation for an undisclosed amount. This acquisition would extend Labcorp’s portfolio of full-service drug development and medical device solutions from discovery to market approval. Toxikon Corporation is a US-based contract manufacturing company that provides outsourcing services for medical devices. Furthermore, in February 2020, Integer Holdings, a US-based advanced medical device outsourcing company acquired Inomec for an undisclosed amount. This acquisition of Inomec will allow Integer to establish a research and development and sales center in Israel, in addition to optimizing its catheter design, clinical, and pilot manufacturing capabilities. Income is an Israel-based medical device outsourcing company. In December 2021, Integer Holdings, a US-based advanced medical device outsourcing company, acquired Oscor Inc. for $220 million. This acquisition of Oscor strengthens Integer’s ability to serve customers by expanding the product offering in steerable sheaths and cardiac and neurostimulation leads and adding low-cost manufacturing capacity to support growth. Oscor is a US-based company that operates in medical device outsourcing services. Major players in the medical device outsourcing market are Flex Ltd., Integer Holdings Corporation, Plexus Corp., Toxikon Inc., Eurofins Scientific SE, Pace Analytical Services Inc., WuXi AppTec Inc., North American Science Associates Inc., Charles River Laboratories International Inc., Creganna, IQVIA, Mitutoyo Corporation, Cardinal Health Inc., Onex Corporation, Te Connectivity Ltd., Nortech Systems Incorporated, Sanmina Corporation, and Sterigenics International LLC. North America was the largest region in the medical device outsourcing market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the medical device outsourcing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the medical device outsourcing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The medical device outsourcing market includes revenues earned by entities by providing services such as design and development. Components and devices manufacturing, process validation and verification, Packaging, regulatory consultation, and full services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global medical device outsourcing market is segmented - 1) By Product: Finished Goods, Electronics, Raw Materials 2) By Device Type: Class I Devices, Class II Devices, Class III Devices 3) By Services: Quality Assurance, Regulatory Affair Services, Product Design Development, Product Testing And Sterilization, Product Implementation, Product Upgrade, Product Maintenance, Contract Manufacturing 4) By Application: Drug Delivery, Dental, Diabetes Care, Cardiology, Other Applications

General data protection regulation (GDPR) refers to a regulatory framework that establishes standards for the gathering and processing of personal data from people living in the European Union (EU). GDPR is used to provide a set of uniform data protection laws among all the participating nations in the European Union (EU). The main types of general data protection regulation services are on-premise and cloud services. On-premises refers to IT infrastructure hardware and software applications that are hosted on-site. This contrasts with IT assets that are hosted by a public cloud platform or remote data center. The offerings involved are data management, data discovery and mapping, data governance, and API management. The organisation size is large enterprises and small and medium-sized enterprises. The various end users involved banking, financial services, and insurance (BFSI), telecom and IT, retail and consumer goods, healthcare and life sciences, manufacturing, and other end-user industries. The general data protection regulation services market research report is one of a series of new reports from The Business Research Company that provides general data protection regulation services market statistics, including general data protection regulation services industry global market size, regional shares, competitors with a general data protection regulation services market share, detailed general data protection regulation services market segments, market trends and opportunities, and any further data you may need to thrive in the general data protection regulation services industry. This general data protection regulation services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global general data protection regulation services market size grew from $1.64 billion in 2022 to $2.04 billion in 2023 at a compound annual growth rate (CAGR) of 24.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The general data protection regulation services market size is expected to grow to $4.78 billion in 2027 at a CAGR of 23.8%. The increase in the number of cyberattacks is expected to propel the growth of the general data protection regulation services market going forward. A cyber attack is an attempt to enter a computer, computing system, or computer network without authorization with the goal of causing harm. Cyber attackers would enable hackers to gain access to a person's or company's financial accounts using sensitive data, among other potentially damaging actions. General data protection regulation services (GDPR) provide a secure way to protect sensitive data from unauthorised access, theft, or exposure. For instance, in 2021, according to the Federal Bureau of Investigation’s Internet Crime Report, a US-based federal agency for investigating cyber attacks and intrusions in the USA, complaints registered under cybercrimes reached a total of 84.73k cases, showing an increase of 7% from 2020. Therefore, an increasing number of cyberattacks is driving the general data protection services market. The increase in the trend of shifting towards new and advanced technology is the key trend gaining popularity in the general data protection regulation services market. Major companies operating in the general data protection regulation services market are focused on developing new technological solutions to strengthen their position. For instance, in January 2020, Black Penny Consulting, a UK-based company operating in general data protection regulation services, developed the compliance space technology. The compliance space is built on a platform that is affordable, simple to use, and breach-sensitive for assisting with instances involving breaches of personal data. This provides a direct platform connection to the consulting partner and is designed to replace time-consuming spreadsheets with a more intuitive software interface that will make compliance management more effective and efficient, including real-time legislative updates. The service is aimed solely at data protection officers and specialist consultants who are tasked with assisting businesses in meeting their GDPR obligations. In January 2021, Veritas, a US-based international data management company, acquired HubStor for an undisclosed amount. This acquisition is expected to improve Hubstor's strong backup-as-a-service technology with the Microsoft Azure public cloud base of Veritas. HubStor is a Canada-based company operating in general data protection regulation services. Major players in the general data protection regulation services market are International Business Machines Corporation, Veritas Technologies LLC, Amazon Web Services (AWS) Inc., Microsoft Corporation, Micro Focus International plc, Absolute Software Corporation, Capgemini SE, Informatica Inc., Iron Mountain Incorporated, Mimecast Services Limited, Oracle Corporation, Proofpoint Inc., SAS Institute Inc., Varonis, and Talend. North America was the largest region in the general data protection regulation services market in 2022. North America is expected to be the fastest-growing region in the forecast period. The regions covered in this general data protection regulation services market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the general data protection regulation services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The general data protection regulation market includes revenues earned by entities by providing services such as legal obligation, vital interests, public task, and legitimate interests. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global general data protection regulation services market is segmented - 1) By Type of Deployment: On-Premise, Cloud 2) By Offering: Data Management, Data Discovery and Mapping, Data Governance, API Management 3) By Organization Size: Large Enterprises, Small and Medium-Sized Enterprises 4) By End User: Banking, Financial Services, and Insurance (BFSI), Telecom and IT, Retail and Consumer Goods, Healthcare and Life Sciences, Manufacturing, Other End-user Industries

The artificial intelligence (AI) in fintech refers to a technology used in the fintech space. AI is a part of fintech companies in terms of collection of data, analyzing information, securing and facilitating transactions, creating customer-centric products, and streamlining processes. It provides stronger security, better analytics, and insights, virtual assistance, and chatbots. The main types of products in AI in fintech are solutions and services. The AI as a solution in fintech consists of decision making, automated customer support, fraud detections, claims management, and automated virtual financial assistants. The deployment modes are cloud and on-premise. The applications include asset management, risk investigation, business analytics, regulatory compliance, data collection, predictive analytics, virtual assistance, and others. The AI in fintech market research report is one of a series of new reports from The Business Research Company that provides AI in fintech market statistics, including AI in fintech industry global market size, regional shares, competitors with an AI in fintech market share, detailed ai in fintech market segments, market trends and opportunities, and any further data you may need to thrive in the AI in fintech industry. This AI in fintech market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global AI in fintech market size grew from $9.15 billion in 2022 to $11.59 billion in 2023 at a compound annual growth rate (CAGR) of 26.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The ai in fintech market size is expected to grow to $31.71 billion in 2027 at a CAGR of 28.6%. The need for fraud detection in fintech or financial institutions is contributing to the growth of AI in the fintech market. Artificial intelligence, or machine learning algorithms, can learn new information from the data collected, the more data that AI manipulates, the more AI can be learned, and the banks can gain deeper insights with AI technology. The biggest advantage of AI is that over time the algorithm builds on collecting more data and learning more about how to use it. The advantage is that it starts the moment the AI is deployed and continues to grow without interruption of contribution. According to PricewaterhouseCoopers’s survey in 2022, a UK-based financial service provider, in the previous 24 months, fraud, corruption, or other economic crimes were reported by 46% of the organizations polled.  Moreover, in September 2021, according to the FintechNews, a Switzerland-based financial and fintech firm, banks are deploying AI-based solutions at an unprecedented rate, spending more than $217 billion on AI applications for middle-office use cases including fraud prevention and risk assessment. The need for fraud detection in fintech drives the market for AI in fintech. Technological Advancement is the key trend gaining popularity in the AI in the fintech market. For instance, in 2021, In India, the Robo-advisory technology refers to the digital platforms that provide financial advice through AI, driven software with zero human intervention. It advises the people to pick up the right stock and even suggests replacing the existing stock in the portfolio based on the factors related to valuations, governance, and performance other things. In May 2020, Cleareye.ai, Inc., a US-based fintech company, acquired AIWare.ai for an undisclosed deal amount. Through this acquisition, Cleareye.ai combines both company teams of AIWare.ai and Cleareye.ai to strengthen their ability to offer solutions such as leveraging artificial intelligence, bionic automation, and advanced analytics. Aiware.ai is an Indian startup that specializes in AI and provides services in the fintech industry. Major players in the AI in fintech market are Microsoft, Google, IBM Corporation, Intel Corporation, Amazon Web Services, IPsoft, Salesforce Inc., Nuance Communications, Next IT Corporation, Trifacta Software Inc., Inbenta Technologies, Zeitgold GmbH, and Onfido. North America was the largest region in the AI in fintech market in 2022. The regions covered in the AI in fintech market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the AI in fintech market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The artificial intelligence (AI) in fintech market consists of sales of web development services, big data development services, custom software development, DevOps services, IoT development services, outsourcing software development. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global AI in fintech market is segmented - 1) By Type: Solutions, Services 2) By Deployment: Cloud, On-premise 3) By Application: Asset Management, Risk Investigation, Business Analytics, Regulatory Compliance, Data Collection, Predictive Analytics, Virtual Assistance, Other Applications

Oncology devices are medical devices used in the diagnosis, management, and treatment of cancer. The main device types of oncology devices are brachytherapy devices and endoscopic devices. Endoscopic devices are medical devices used in the diagnosis, management, and treatment of cancer. It is used to look internally at a body cavity or organ. These are used in various therapies such as chemotherapy, hormone therapy, biotherapy/immunotherapy, and radiation therapy that are used by various end-users such as hospitals, cancer research institutes, and others. The oncology devices market research report is one of a series of new reports from The Business Research Company that provides oncology devices market statistics, including oncology devices industry global market size, regional shares, competitors with a oncology devices market share, detailed oncology devices market segments, market trends and opportunities, and any further data you may need to thrive in the oncology devices industry. This oncology devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global oncology devices market grew from $107.81 billion in 2022 to $128.33 billion in 2023 at a compound annual growth rate (CAGR) of 19.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The oncology devices market is expected to grow from $250.74 billion in 2027 at a CAGR of 18.2%. A growing number of cancer cases across the globe is anticipated to boost the demand for the oncology devices market. Cancer is a major health problem across the globe and is the second leading cause of death in the USA. The increasing incidence of cancer is contributing to the surge in demand for oncology devices to treat cancer patients. The four most common types of cancer globally are prostate, lung, bowel, and female breast cancer, accounting for 43% of all new cancer cases. According to the American Cancer Society, there were 1.9 million new cases and 608,570 cancer deaths in 2021 in the USA. Therefore, the rise in cancer incidence is anticipated to boost the demand for the oncology drugs market. The low per capita expenditure on healthcare in developing countries is anticipated to limit the growth of the oncology devices market. The per capita expenditure on healthcare is very low in emerging economies such as China, India, and Indonesia as compared to developed nations. For instance, in 2020, according to India's total per capita, government spending on healthcare has almost doubled from ?1,008 per person in the year 15 to ?1,944 in the year 2020 but is still low. The total expenditure by the Centre and states for the year 2020 was ?2.6 trillion, or 1.29% of GDP, as well as establishment expenditure comprising salaries, gross budgetary help to different institutions and hospitals, and transfers to states centrally sponsored schemes like Ayushman Bharat. Major companies in the market, research institutes, and governments are continuously focusing on developing new devices to treat cancer patients. For instance, AIROS Medical Inc., a medical technology company based in the USA, launched AIROS 6 sequential compression therapy device and garment system to treat breast cancer patients. The advanced technology expanded upper extremity post-mastectomy treatment options for patients with lymphedema. In May 2021, GE Healthcare, a US-based manufacturer of medical devices, acquired Zionexa for an undisclosed amount. The acquisition would help GE healthcare to develop more personalised treatments for cancer. Zionexa is a French developer of cancer and neurology biomarkers. Major players in the oncology devices market are Eckert & Ziegler BEBIG, Oncura Inc., GE Healthcare, Medtronic PLC., Varian Medical Systems Inc., Elekta AB, Theragenics Corporation, Accuray Incorporated, Roche Diagnostics, and IBA Group. North America was the largest region in the oncology devices market in 2022. Asia-Pacific was the second largest region in the global oncology devices market report. The regions covered in the global oncology devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the oncology devices market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The oncology devices market consists of sales of brachytherapy devices and endoscopic devices. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global oncology devices market is segmented - 1) By Device Type: Brachytherapy Devices, Endoscopic Devices 2) By Therapy: Chemotherapy, Hormone Therapy, Biotherapy/Immunotherapy, Radiation Therapy 3) By End User: Hospitals, Cancer Research Institutes, Other End Users

Oncology biosimilars refer to biologically similar drugs or medications that are physiologically comparable to biologic cancer treatments. Infection risk is increased by decreased white blood cell counts, which can be treated as a side effect of cancer therapy. The main drug types of oncology biosimilars are monoclonal antibodies, immunomodulators, hematopoietic agents, and granulocyte colony-stimulating factor (G-CSF). Immunomodulators are a class of drugs that primarily target pathways involved in the treatment of multiple myeloma and a few other cancers. The types of cancer treated include breast cancer, colorectal cancer, blood cancer, neutropenia cancer, and non-small cell lung cancer, and the various distribution channels involved are hospital pharmacies, retail pharmacies, and online pharmacies. The oncology biosimilars market research report is one of a series of new reports from The Business Research Company that provides oncology biosimilars market statistics, including oncology biosimilars industry global market size, regional shares, competitors with an oncology biosimilars market share, detailed oncology biosimilars market segments, market trends and opportunities, and any further data you may need to thrive in the oncology biosimilars industry. This oncology biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global oncology biosimilars market grew from $4.19 billion in 2022 to $5.38 billion in 2023 at a compound annual growth rate (CAGR) of 28.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The oncology biosimilars market is expected to grow from $12.83 billion in 2027 at a CAGR of 24.3%. The expiration of the patent of biologics used for the treatment of cancer is driving the production of new oncology biosimilars. Biologics can be patented for a limited period and the expiration of patents for biologics allows the development of new biosimilars. Biologics are targeted drugs synthesized from living organisms that induce the immune system to attack cancer cells. Biosimilars are similar to biologics but are not identical and offer the same effectiveness as biologics at a reduced cost. According to the Center for Biosimilars, patents on nearly 20 oncology biologics will expire by 2023, leading to the development of new biosimilars in cancer care. The increased number of patent expiry is expected to boost the demand for the production of new oncology biosimilars, thus, driving the market growth for oncology biosimilars. The lack of awareness of biosimilars among primary care physicians (PCPs) and specialists limits the growth of the oncology biosimilars market. Biosimilars are manufactured from cell lines and offer the same effectiveness as biologics. However, a lack of detailed awareness of the biosimilars amongst the prescribers reduces the prescriptions of biosimilars affecting the biosimilar market. For instance, as reported by the Health Research Institute of PricewaterhouseCoopers, out of 442 clinicians surveyed 55% of clinicians were unfamiliar with biosimilars and 35% were reluctant to prescribe them due to concerns including the safety of the follow-on biologic. Thus, the lack of awareness about biosimilars among primary care physicians (PCPs) and specialists restricts the growth of the oncology biosimilars market. The pharmaceutical companies are increasingly investing in research and development to produce new oncology biosimilars. The companies are exploiting the growth potential of the rising biosimilar market by investing in their research and development (R&D) processes to support the research and production process of new biosimilars. For instance, in February 2021, Coherus and Junshi Biosciences announced a collaboration in which Coherus would in-license toripalimab, an anti-PD-1 antibody in the US and Canada. Coherus plan to build a leading immuno-oncology franchise using cash from its commercial biosimilar business. Also, in 2019, Biocon, India’s largest biotechnology company invested to acquire some assets of Pfizer Healthcare to set up an R&D facility to boost biosimilar development. Major players in the oncology biosimilars market are Bitcoin, Celltrion Inc., Dr. Reddy's Laboratories Ltd., Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Pfizer Inc., Apotex Inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, BIOCAD, Amgen, Hospira, F Hoffmann-La Roche, Baxter, Sanofi, Mylan, and F Hoffmann-La Roche. North America was the largest region in the global oncology biosimilars market in 2022. The Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the global oncology biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the oncology biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The oncology biosimilars market consists of sales of Ogivri, Herzuma, Ontruzant, and Trazimera. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global oncology biosimilars market is segmented - 1) By Drug Type: Monoclonal Antibodies, Immunomodulators, Hematopoietic Agents, Granulocyte Colony-Stimulating Factor (G-CSF) 2) By Cancer Type: Breast Cancer, Colorectal Cancer, Blood Cancer, Neutropenia Cancer, Non-Small Cell Lung Cancer, Other Cancer Types 3) By Distribution Type: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

The virtual clinical trials refers to remote or decentralized clinical trials or studies that incorporate digital health technologies and enable remote participation outside the traditional brick-and-mortar clinical trial site using tablets, smartphone apps, or wearable sensors. Virtual clinical trials allow significant digital changes in clinical research methodology, resulting in a more patient-centric ecosystem. The main design types of virtual clinical trials include observational trials, interventional trials, and expanded access trials. The observational trials refer to virtual clinical trials solutions and services used in the observational trials. Observational studies aim to learn what occurs to people in various contexts. The study team observes the participants but does not influence the therapies they get. The virtual clinical trials are used in Phase I, Phase II, Phase III, and Phase IV, and they are used in clinical trials of drugs are devices used in the treatment of CNS, autoimmune/inflammation, cardiovascular diseases, metabolic/endocrinology, infectious diseases, oncology, genitourinary, ophthalmology, and others. The virtual clinical trials market research report is one of a series of new reports from The Business Research Company that provides virtual clinical trials market statistics, including virtual clinical trials industry global market size, regional shares, competitors with a virtual clinical trials market share, detailed virtual clinical trials market segments, market trends and opportunities, and any further data you may need to thrive in the virtual clinical trials industry. This virtual clinical trials market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global virtual clinical trials market size grew from $9.68 billion in 2022 to $10.49 billion in 2023 at a compound annual growth rate (CAGR) of 8.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The virtual clinical trials market size is expected to grow to $14.82 billion in 2027 at a CAGR of 9.0%. The increasing investments by the government and pharmaceutical companies in the R&D for the development of new vaccines and drugs are driving the growth of the virtual clinical trials market. The R&D divisions in the medical industry are increasingly utilizing virtual clinical trial solutions and services to increase quality assurance and clinical data management of drugs and their products. For instance, according to the study published in Research!America, a non-profit medical and health research advisory, the medical and health R&D investment in the USA was recorded at $241.5 billion in 2020 an 11.1% increase from 2019. Additionally, in June 2021, an article published by Mckinsey, COVID-19 pandemic, has catalyzed the adoption of decentralized clinical trials by pharma companies while highlighting the critical benefits of virtual trials and improving the patient and physician experience. Therefore, the increasing investments by the government and pharmaceutical companies in new vaccines and drug development are driving the growth of virtual clinical trials. Technology advancement is a key trend gaining popularity in the virtual clinical trials market. Major companies operating in the virtual clinical trials market are focused on providing technologically-advanced solutions to meet fast-growing industry demands and strengthen their market position. These companies are implementing new generation virtual clinical technologies into their services, such as wearable technologies, mHealth, blockchain, cloud computing, EMR integration, actionable data, threshold monitoring, AI, SFTP, ETL services, and others. For instance, In April 2022, Unlearn.AI, a US-based startup, will launch a new digital twin RCTs technology for clinical trials that enables smaller control groups while maintaining power and generating evidence suitable for supporting regulatory decisions using AI and historical data. In December 2020, Signant Health, USA-based evidence generation company acquired VirTrial for an undisclosed amount. Through this acquisition, Signant Health would enhances its software stack to provide sponsors with superior evidence generation across traditional, decentralized, and hybrid trial models. VirTrial is a US-based company involved in offering telehealth platform for managing decentralized and virtual clinical trials. Major players in the virtual clinical trials market are ICON, plc, Parexel International, IQVIA, Covance, PRA Health Sciences, LEO Innovation Lab, Medidata, Oracle Inc., CRF Health, Clinical Ink, Inc., Medable, Inc., Signant Health, Thread Research, Halo Health Systems, and Croprime. North America was the largest region in the virtual clinical trials market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the virtual clinical trials market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the virtual clinical trials market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The virtual clinical trials market includes revenues earned by entities by providing services such as pilot studies and feasibility studies, prevention trials, screening trials, treatment trials, multi-arm multi-stage (mams) trials, cohort studies, case control studies, and cross sectional studies. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global virtual clinical trials market is segmented - 1) By Design: Observational Trials, Interventional Trials, Expanded Access Trials 2) By Phases: Phase I, Phase II, Phase III, Phase IV 3) By Indication: CNS, Autoimmune/Inflammation, Cardiovascular Disease, Metabolic/Endocrinology, Infectious Disease, Oncology, Genitourinary, Ophthalmology, Other Indications

Services refer to transactions between a buyer and a seller without transferring any physical goods or commodities, involving the use of resources, experience, skill, ingenuity, and intelligence. It mainly involves the use of resources, experience, skill, ingenuity, and intelligence. The main types of services include Civic Services, Real Estate, Leasing, Commercial Services, Personal Services, and Repair and Maintenance. Civic service is defined as a structured period of significant engagement and commitment to the local, national, or international community that is acknowledged and recognized by society, with little or no monetary recompense to the individual. The components including hardware, software, and service. The different modes include online and offline. The services market research report is one of a series of new reports from The Business Research Company that provides services market statistics, including services industry global market size, regional shares, competitors with a services market share, detailed services market segments, market trends, and opportunities, and any further data you may need to thrive in the services industry. This services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global services market grew from $13,978.41 billion in 2022 to $15,223.84 billion in 2023 at a compound annual growth rate (CAGR) of 8.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The services market is expected to grow to $20,650.56 billion in 2027 at a CAGR of 7.9%. Rapid advances in technology are expected to drive innovation in different sectors of the services industry, thus driving the market during the forecast period. Areas of rapid technological change included electronic equipment, automobiles, and electronics, which in turn will lead to an increase in services for that equipment. Furthermore, technologies such as 3D printing, artificial intelligence, and big data analytics are increasingly being used, resulting in higher productivity, lower operating costs, and higher margins. Lower operating costs lead to higher margins, this allows companies to increase product portfolio and enter new markets by making investments made through cost savings. IoT applications are also being integrated into services to enable services such as remote monitoring, and central feedback systems, and to offer other services. These factors are expected to drive the services market going forward. The outbreak of COVID-19 disease (COVID-19) has acted as a massive restraint on the services market in 2020 as the need for services offered by these establishments declined due to lockdowns imposed by governments globally. COVID-19 is an infectious disease with flu-like symptoms including fever, cough, and difficulty in breathing. The virus was first identified in 2019 in Wuhan, Hubei province of the People's Republic of China, and spread globally including Western Europe, North America, and Asia. Steps by national governments to contain the transmission have resulted in a decline in economic activity with countries entering a state of 'lockdown' and the outbreak had a negative impact on businesses throughout 2020 and into 2021. However, it is expected that the services market will recover from the shock across the forecast period as it is a 'black swan event and not related to ongoing or fundamental weaknesses in the market or the global economy. With companies focusing on core business operations, automated billing systems are widely being used to minimize billing errors and reduce costs. Automated systems generate and send electronic copies of invoices directly to customers. Automated billing systems can result in savings of 60-80% compared to traditional paper-based billing systems. Automated billing systems also enable tracking of unpaid bills, automating payment reminders and recurring invoices, managing discounts, and coupons, and creating of customized invoices. These systems also generate real-time reports on sales, orders, and budgets that help track business performance. Some of the popular automated billing systems include Zoho Invoice, QuickBooks, Invoice2go, and Intacct. Major companies in the services market include BCD Travel, Enterprise Holdings Inc., Randstad Holding NV, Adecco Group, Travel Leaders Group, TUI Group, Recruit Holdings, ManpowerGroup Inc., Berkshire Hathaway Inc., and Waste Management Inc. Asia-Pacific was the largest region in the services market in 2022. North America was the second-largest region in the services market. The regions covered in the services market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the services market are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, Vietnam. The services market consists of revenue earned by entities by providing services to equipment and machinery repairing, promoting or administering religious activities, grant making, advocacy, and providing dry-cleaning and laundry services, personal care services, death care services, pet care services, photofinishing services, and temporary parking services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global services market is segmented - 1) By Type: Civic Services, Real Estate, Leasing, Commercial Services, Personal Services, Repair and Maintenance 2) By Component: Hardware, Software, Service 2) By Mode: Online, Offline Subsegments Covered: Religious Organizations, NGOs And Charitable Organizations, Political Organizations, Unions And Associations, Real Estate Rental, Real Estate Agency and Brokerage, Automotive Equipment Leasing, Consumer Goods And General Rental Centers, Machinery Leasing, Lessors Of Nonfinancial Intangible Assets, Office Administrative Services, Facilities Support Services, Employment Services, Business Support Services, Travel Arrangement And Reservation Services, Waste Management And Remediation Services, Investigation And Security Services, Services to Buildings And Dwellings, Other Support Services,, Personal Care Services, Death Care Services, Dry-Cleaning And Laundry Services, Other Personal Services, Private Household Services, Automotive Repair and Maintenance, Commercial and Industrial Machinery and Equipment Repair and Maintenance, Electronic and Precision Equipment Repair and Maintenance, Personal Goods Repair And Maintenance

The pharmaceuticals market consists of sales of pharmaceuticals and related services by entities (organizations, sole traders and partnerships) that produce pharmaceuticals used in treating diseases. Pharmaceuticals can be any type of drugs that are used for medicinal purposes, in the treatment of diseases. This industry includes establishments that produce biologics and pharmaceutical drugs. The main types of pharmaceuticals are pharmaceutical drugs and biologics. Biologics are products that are made from or contain components of living organisms. The various nature included are organic and conventional that are distributed through supermarkets/hypermarkets, convenience stores, e-commerce and others. The global pharmaceuticals market size is expected to grow from $1454.66 billion in 2021 to $1587.05 billion in 2022 at a compound annual growth rate (CAGR) of 9.1%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The pharmaceuticals market is expected to reach $3201.02 billion in 2026 at a CAGR of 19.2%. The population profile of most countries is becoming older. According to the WHO, by 2030, one in every six people on the planet will be 60 or older. The proportion of the population aged 60 and up will rise from 1 billion in 2020 to 2.2 billion by 2050. This rise in the aging population increased the patient pool of many chronic diseases such as rheumatoid arthritis, hypertension, diabetes and cancer. The increase in the patient pool drove the demand for pharmaceuticals used in the treatment of these diseases, significantly impacting market growth during this period. The biologics market growth will be hinder by severe shortage of skilled workforce for developing biologics drugs which require specialized skillsets. These skillsets are limited to some research organizations and medical equipment companies in the USA and Europe. According to a study conducted by the consulting firm Mercer, the United States will face significant healthcare worker shortages in the coming decade. The firm predicts a shortage of more than 400,000 home health aides and 29,400 nurse practitioners by 2025. This shortage will rise in competition and salaries for the limited talent pool available for biologics manufacturing, thereby limiting growth of the market during the forecast period. Pharmaceutical companies are offering drugs for customized individual treatment for various diseases. Personalized medicine, also referred to as precision medicine, aims to provide medical care according to the patient’s individual characteristics and genetic makeup. Precision therapies are increasingly being adopted as firms increasingly let go of the one-size-fits-all model for common medical conditions. Major companies such as GSK, Teva Pharmaceuticals and AstraZeneca are investing in development of personalized medicines. Major companies in the pharmaceuticals market include Johnson & Johnson, Novartis AG, Bristol-Myers Squibb, AbbVie, Sanofi S.A, Pfizer Inc., GlaxosmithKline, F. Hoffmann-La Roche Ltd., and Merck & Co, AstraZeneca North America was the largest region in the pharmaceuticals market in 2021. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the pharmaceuticals market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the pharmaceuticals market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela and Vietnam. The global pharmaceuticals market is segmented - 1) By Type: Pharmaceutical Drugs, Biologics 2) By Distribution Channel: Supermarkets/Hypermarkets, Convenience Stores, E-Commerce, Others 3) By Nature: Organic, Conventional Subsegments Covered: Cardiovascular Drugs, Dermatology Drugs, Gastrointestinal Drugs, Genito-Urinary Drugs, Hematology Drugs, Anti-Infective Drugs, Metabolic Disorders Drugs, Musculoskeletal Disorders Drugs, Central Nervous System Drugs, Oncology Drugs, Ophthalmology Drugs, Respiratory Diseases Drugs, Monoclonal Antibodies (MAbs), Therapeutic Proteins, Vaccines